Transcriptome wide changes in long noncoding RNAs in diabetic ischemic heart disease

Amit Kumar Rai,Natarajaseenivasan Suriya Muthukumaran,Noemi Nisini,Tiffany Lee,Ioannis D. Kyriazis,Claudio de Lucia,Michela Piedepalumbo,Rajika Roy,Shizuka Uchida,Konstantinos Drosatos,Malik Bisserier,Rajesh Katare,David Goukassian,Raj Kishore,Venkata Naga Srikanth Garikipati

DOI: https://doi.org/10.1186/s12933-024-02441-6

IF: 8.949

2024-10-19

Cardiovascular Diabetology

Abstract:More than 10% of adults in the United States have type 2 diabetes mellitus (DM) with a 2–4 times higher prevalence of ischemic heart disease than the non-diabetics. Despite extensive research approaches to limit this life-threatening condition have proven unsuccessful, highlighting the need for understanding underlying molecular mechanisms. Long noncoding RNAs (lncRNAs), which regulate gene expression by acting as signals, decoys, guides, or scaffolds have been implicated in diverse cardiovascular conditions. However, their role in ischemic heart disease in DM remains poorly understood. We provide new insights into the lncRNA expression profile after ischemic heart disease in DM mice. We performed unbiased RNA sequencing of well-characterized type 2 DM model db/db mice or its control db/+ subjected to sham or MI surgery. Computational analysis of the RNA sequencing of these LV tissues identified several differentially expressed lncRNAs between (db/db sham vs. db/db MI) including Gm19522 and Gm8075. lncRNA Gm-19522 may regulate DNA replication via DNA protein kinases, while lncRNA Gm-8075 is associated with cancer gene dysregulation and PI3K/Akt pathways. Thus, the downregulation of lncRNAs Gm19522 and Gm8075 post-MI may serve as potential biomarkers or novel therapeutic targets to improve cardiac repair/recovery in diabetic ischemic heart disease.

cardiac & cardiovascular systems,endocrinology & metabolism